Multiple Myeloma Clinical Trial
Official title:
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
NCT number | NCT01045382 |
Other study ID # | TJB0909 |
Secondary ID | |
Status | Terminated |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 2010 |
Est. completion date | August 2021 |
Verified date | August 2021 |
Source | University of Liege |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning. Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, it has been shown that infusion of third party MSC in HSC transplantation could be successfully used as treatment for grade II-IV steroid-refractory acute graft versus host disease. One hundred and twenty patients with HLA-mismatched donors will be included over 6 years at multiple centers across Belgium through the transplant committee of the Belgian Hematological Society. The conditioning regimen will consist of fludarabine and 2 Gy TBI, followed by the infusion of donor HSC. Patients will be randomized 1/1 in double-blind fashion to receive or not MSC (1.5-.3.0 x106/kg) from third-party (either haploidentical family members or unrelated volunteer) donors on day 0. Postgrafting immunosuppression will combine tacrolimus and MMF. Except for the collection, expansion and infusion of MSC, the clinical management of the patient will not differ from that of routine NM-HCT.
Status | Terminated |
Enrollment | 39 |
Est. completion date | August 2021 |
Est. primary completion date | August 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 75 Years |
Eligibility | Inclusion Criteria: - Theoretical indication for a standard allo-transplant, but not feasible because: Age > 55 yrs. Unacceptable end organ performance. Patient's refusal. - Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant. - Male or female; fertile female patients must use a reliable contraception method - Age = 75 year old - Informed consent given by patient or his/her guardian if of minor age. - One or two HLA mismatches with PBSC: - One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1 - Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1 - One antigenic mismatch: 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1. - One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1 - Patients with one single allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1 can also be included in the protocol. - Hematological malignancies confirmed histologically and not rapidly progressing: - AML in complete remission - ALL in complete remission - CML unresponsive/intolerant to Imatinib but not in blast crisis - Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis - MDS with <5% blasts - Multiple myeloma not rapidly progressing - CLL - Non-Hodgkin's lymphoma (aggressive NHL should be chemosensitive) - Hodgkin's disease Exclusion Criteria: - Any condition not fulfilling inclusion criteria - HIV positive - Terminal organ failure, except for renal failure (dialysis acceptable) - Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia; uncontrolled hypertension - Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen - Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease - Uncontrolled infection, arrhythmia or hypertension - Previous radiation therapy precluding the use of 2 Gy TBI - 10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC. |
Country | Name | City | State |
---|---|---|---|
Belgium | Hôpital Stuyvenberg | Antwerpen | |
Belgium | AZ St-Jan | Brugge | Flanders West |
Belgium | Bordet Institute | Brussels | |
Belgium | St-Luc UCL | Brussels | Brabant |
Belgium | Vrije Universiteit Brussel | Brussels | |
Belgium | UZA | Edeghem | Antwerpen |
Belgium | UZ Gent | Gent | Flanders Ost |
Belgium | AZ Gasthuisberg Leuven | Leuven | Flamish Brabant |
Belgium | CHU-ULg | Liège | |
Belgium | Cliniques Universitaires Mont-Godinne | Yvoir | Namur |
Lead Sponsor | Collaborator |
---|---|
University of Liege | AZ Sint-Jan AV, AZ-VUB, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Jules Bordet Institute, Universiteit Antwerpen, University Hospital, Ghent, Ziekenhuis Netwerk Antwerpen (ZNA) |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | One-year overall survival in the 2 arms. | One year | ||
Secondary | Incidence of grade II-IV and grade III-IV acute GVDH | 100 days | ||
Secondary | Number of absolute donor T cells after HCT in each arm | 28 | ||
Secondary | Cumulative incidence of non-relapse mortality | 100, 365 and 730 days | ||
Secondary | Incidence of extensive chronic GVHD in each arm | 365 days | ||
Secondary | Incidence of graft rejection in each arm. | 365 days | ||
Secondary | Quality and timing of immunologic reconstitution in each arm. | 100, 365 and 730 days | ||
Secondary | Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC | 40 days | ||
Secondary | Proportion of patients with measurable disease at HCT who achieve a complete response in each arm. | 100, 365 and 730 days | ||
Secondary | Cumulative incidence of relapse | 365 and 730 days | ||
Secondary | Incidence of progression-free survival | 365 and 730 days | ||
Secondary | Incidence of infections | 100 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |